NOREPINEPHRINE, 8 mg per 250 mL, (32 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-676-01.
Published January 5, 2022 · Recall initiated: November 12, 2021
Summary
FDA records drug Class II recall D-0321-2022, published January 5, 2022 and initiated November 12, 2021. Recalling firm: SterRx, LLC; Status: Terminated; Reported quantity: 74,508 bags; Lot: S21162/BTT 13-Nov-21 S21163/BTU 13-Nov-21 S21167/BTY 19-Nov-21 S21174/BUF 20-Nov-21 S21175/BUG 21-Nov-21 S21217/BVS 12-Dec-21 S21218/BVT 12-Dec-21 S21219/BVU 16-Dec-21 S21241/BWL 24-Dec-21 S21281/BXY 20-Jan-22 S21282/BXZ 23-Jan-22 S21283/BYA 22-Jan-22 S21297/BYN 28-Jan-22 S21340/CAA 27-Feb-22 S21342/CAC 5-Mar-22 S21352/CAL 6-Mar-22 S21359/CAS 11-Mar-22 S21362/CAV 12-Mar-22 S21368/CBB 13-Mar-22 S21369/CBC 19-Mar-22 S21415/CCX 7-Apr-22 S21419/CDB 7-Apr-22 S21434/CDP 16-Apr-22. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- SterRx, LLC
- Distributor
- U.S.A. Nationwide
- Lot
- S21162/BTT 13-Nov-21 S21163/BTU 13-Nov-21 S21167/BTY 19-Nov-21 S21174/BUF 20-Nov-21 S21175/BUG 21-Nov-21 S21217/BVS 12-Dec-21 S21218/BVT 12-Dec-21 S21219/BVU 16-Dec-21 S21241/BWL 24-Dec-21 S21281/BXY 20-Jan-22 S21282/BXZ 23-Jan-22 S21283/BYA 22-Jan-22 S21297/BYN 28-Jan-22 S21340/CAA 27-Feb-22 S21342/CAC 5-Mar-22 S21352/CAL 6-Mar-22 S21359/CAS 11-Mar-22 S21362/CAV 12-Mar-22 S21368/CBB 13-Mar-22 S21369/CBC 19-Mar-22 S21415/CCX 7-Apr-22 S21419/CDB 7-Apr-22 S21434/CDP 16-Apr-22
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANorepinephrine 16 mg per 250 mL (64 mcg per mL) in 0.9% Sodium Chloride, 250 mL Single Dose bag, packaged inJuly 26, 2023
- FDASodium Bicarbonate in 5% Dextrose Injection, 150 mEq per 1,000 mL (12.6 mg per mL), 1,000 mL Single Dose bag,July 26, 2023
- FDANorepinephrine 4 mg per 250 mL (16 mcg per mL) in 0.9% Sodium Chloride, 250 mL Single Dose bag, packaged inJuly 26, 2023
- FDANorepinephrine 8 mg per 250 mL (32 mcg per mL) in 0.9% Sodium Chloride, 250 mL Single Dose bag, packaged inJuly 26, 2023
- FDANOREPINEPHRINE, 4 mg per 250 mL, (18 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 IdahoJanuary 5, 2022
- FDANOREPINEPHRINE, 16 mg per 250 mL, (64 mcg per mL) in 0.9% Sodium Chloride Injection, SterRx, 141 Idaho Ave.,January 5, 2022
Questions about this recall
Was NOREPINEPHRINE, 8 mg per 250 mL, (32 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-676-01. recalled?
Yes. FDA published recall D-0321-2022 on January 5, 2022. Reported hazard: Lack of Assurance of Sterility
What should I do if I have this product?
Voluntary: Firm initiated · Press Release